- 1.
Stumvoll M, Goldstein BJ, van Haeften TW. Type 2-diabetes: principles of pathogenesis and therapy. Lancet 2005; 365: 133 – 46.
- 2.
Stratton IM, Adler AI, Neil HA et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321: 405 – 12.
- 3.
Nathan DM, Cleary PA, Backlund JY et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005; 353: 2643 – 53.
- 4.
Nathan DM, Buse JB, Davidson MB et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2006; 29: 1963 – 72.
- 5.
Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356: 2457 – 71.
- 6.
Bradburn MJ, Deeks JJ, Berlin JA et al. Much ado about nothing: a comparison of the performance of meta-analytical tools with rare events. Stat Med 2007; 26: 53 – 77.
- 7.
Diamond GA, Bax L, Kaul S. Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death. Ann Intern Med 2007; E-publisert 6.8.2007.
- 8.
Snapinn SM. Noninferiority trials. Curr Control Trials Cardiovasc Med 2000; 1: 19 – 21.
- 9.
Home PD, Pocock SJ, Beck-Nielsen H et al. Rosiglitazone evaluated for cardiac outcomes and regulation of glycaemia in diabetes (RECORD): study design and protocol. Diabetologia 2005; 48: 1726 – 35.
- 10.
Home PD, Pocock SJ, Beck-Nielsen H et al. Rosiglitazone evaluated for cardiovascular outcomes – an interim analysis. N Engl J Med 2007; 357: 28 – 38.
- 11.
Psaty BM, Furberg CD. The record on rosiglitazone and the risk of myocardial infarction. N Engl J Med 2007; 357: 67 – 9.
()
Denne artikkelen ble publisert for mer enn 12 måneder siden, og vi har derfor stengt for nye kommentarer.